almotriptan is the only oral triptan approved in the usa for the treatment of migraine in adolescent from 12 to 17 years of age the efficacy and tolerability of almotriptan has been studied in numerous randomised control led trials totaling more than 4800 adults with either moderate or severe attacks of migraine its efficacy is significantly more effective than placebo and alleviates nausea photophobia and phonophobia linked to migraine attacks almotriptan has similar efficacy as a standard dose of sumatriptan another triptan drug and fewer adverse effects as with other triptans almotriptan should not be used in patients with a history symptoms or signs of ischaemic heart disease myocardial infarction angina pectoris documented silent ischaemia prinzmetal s angina or severe hypertension and uncontrolled mild or moderate hypertension other contraindications are previous cerebrovascular accident cva or transient ischaemic attack tia peripheral vascular disease severe hepatic impairment concomitant administration of ergotamine ergotamine derivatives including methysergide and other 5 ht1 agonists almotriptan has proved to have an adverse effects profile similar to placebo when used following the summary of product characteristics instructions see references like all triptans almotriptan has a high and specific affinity for serotonin 5 ht receptors binding of the drug